CA-MP-BIOMEDICALS
11.12.2014 20:50:48 CET | Business Wire | Pressemeddelelse
MP Biomedicals, LLC, a leading provider of life science reagents, fine chemicals and diagnostic products, announced today that it has received FDA approval on the MP Diagnostics HTLV (Human T-Cell Lymphotropic Virus) Blot 2.4, a Western Blot for HTLV confirmatory testing and viral type discrimination. This approval signifies the first ever FDA approved HTLV confirmatory assay in the United States.
MP Biomedicals continues to be a leader in immunoblot confirmatory diagnostics with over 25 years of research and development in Immunoblot products. Immunoblot assays have stood the test of time, surpassing its competitors in delivering high-performance results. Many worldwide experts consider the MP Biomedicals immunoblot product line the benchmark in confirmatory diagnostics.
An important differentiator of the HTLV Blot 2.4 design is the incorporation of the patented GD21 recombinant envelope protein, recombinant proteins specific to HTLV-I and HTLV-II, and HTLV viral lysate. Sensitivity and specificity are greatly enhanced, providing laboratories with reliable results for both conformation and differentiation between HTLV-I and HTLV-II infections. This information is crucial when counseling infected individuals, due to the different health implications of the two HTLV viral types.
“This marks the first FDA-approved infectious disease assay in the company’s product portfolio, and we plan to continue building on this milestone,” said Milan Panic, Chairman and CEO. “Our focus on quality remains our top priority.”
HTLV is a retrovirus which predominantly infects human T-lymphocytes. While the vast majority of people infected with HTLV are asymptomatic carriers, HTLV infection is known to cause Adult T-cell leukemia/lymphoma (ATLL) and HTLV-I associated myelopathy (HAM) in some patients. HTLV can be transmitted through unprotected sexual contact; from an infected mother to her baby by prolonged breast feeding; sharing of needles by drug users; and transfusion of infected donor blood.
About MP Biomedicals, LLC
MP Biomedicals is a worldwide corporation headquartered in Southern California, with ISO-certified and FDA-approved manufacturing and distribution facilities throughout the globe. MP Biomedicals manufactures and sells more than 55,000 products and is one of the only companies in the industry to offer a comprehensive line of life science, fine chemical and diagnostic products. MP Biomedicals has a long-standing history of marketing high-quality diagnostic products, including Western Blots, ELISAs, Rapid tests and analyzer solutions. A vast network of global distributors, satellite facilities and offices throughout Europe, Asia, Australia and the Americas ensures product delivery whenever and wherever needed.
About Milan Panic
Milan Panic serves as Chairman and Chief Executive Officer of MP Biomedicals, formerly ICN Biomedicals. He was Founder and former Chairman of the Board and Chief Executive Officer of ICN Pharmaceuticals, Inc., a global health care company, currently Valeant, NYSE: VRX.
Milan Panic founded ICN in 1959 after defecting from his native Yugoslavia, and built the company to $1 billion in annual sales before retiring as CEO in 2002. At that time, ICN was listed as the 49th largest pharmaceutical company in the world.
For more information please visit www.mpbio.com .
Contact:
MP Biomedicals, LLC
Media Contact
Kurtis Styhr
Director
of Sales & Marketing, Diagnostics
kurt.styhr@mpbio.com
Tel:
800.854.0530
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum